0 34

Cited 0 times in

Non-steroidal anti-inflammatory drugs in patients with stable ankylosing spondylitis receiving tumor necrosis factor inhibitor: continued vs withdrawn

Authors
 Jung Hwan Park  ;  Oh Chan Kwon  ;  Min-Chan Park 
Citation
 CLINICAL RHEUMATOLOGY, Vol.39(12) : 3669-3675, 2020-12 
Journal Title
 CLINICAL RHEUMATOLOGY 
ISSN
 0770-3198 
Issue Date
2020-12
Keywords
Ankylosing spondylitis ; Disease activity ; Non-steroidal anti-inflammatory drug ; Tumor necrosis factor inhibitor
Abstract
Objective: To investigate the effect of non-steroidal anti-inflammatory drugs (NSAIDs) on disease activity in patients with stable ankylosing spondylitis (AS) receiving tumor necrosis factor inhibitor (TNFi). Methods: In this retrospective observational study, a total of 189 patients with stable AS receiving TNFi were included. Patients were classified into NSAID withdrawn group (n = 48) and NSAID continued group (n = 141), according to the use of NSAIDs. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were measured every 3 months, and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was measured every 6 months as parameters to evaluate disease activity. ESR, CRP, and BASDAI at each time point, and time-averaged values of each parameter during the observation period of 1 year were compared between the two groups. Repeated-measure ANOVA was performed to compare changes in disease activity parameters during the observation period between the two groups. Results: The level of ESR, CRP, and BASDAI at baseline and during the observation period did not differ between the two groups. The time-averaged values of ESR (p = 0.096), CRP (p = 0.136), and BASDAI (p = 0.421), and changes of ESR (p = 0.101), CRP (p = 0.714), and BASDAI (p = 0.613) during the observation period were not significantly different between the two groups. Conclusion: The continued use of NSAIDs in patients with stable AS receiving TNFi had no additional benefit in controlling the disease activity, as compared to patients who withdrew NSAIDs. Considering the risk of toxicity of long-term NSAID use, withdrawal of NSAIDs in stable AS patients receiving TNFi may be preferable. Key points • There is a lack of supportive evidence whether to continue or withdraw non-steroidal anti-inflammatory drugs (NSAIDs) in patients with stable ankylosing spondylitis (AS) receiving tumor necrosis factor inhibitor (TNFi). • Compared with patients who withdrew NSAIDs, continuing NSAIDs in patients with stable AS receiving TNFi had no additional benefit in controlling disease activity. • The results of the present study provide evidence that supports withdrawal of NSAIDs in patients with stable AS receiving TNFi.
Full Text
https://link.springer.com/article/10.1007%2Fs10067-020-05157-6
DOI
10.1007/s10067-020-05157-6
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kwon, Oh Chan(권오찬)
Park, Min Chan(박민찬) ORCID logo https://orcid.org/0000-0003-1189-7637
Park, Jung Hwan(박정환)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/180684
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links